STAAR Surgical has seen its share price struggle over the longer term, even after a recent bounce, which puts a spotlight on whether the current valuation lines up with the cash the business can realistically generate. For investors watching the recent moves and the legal headlines, the core issue is whether the stock price now fairly reflects STAAR Surgical's cash flow potential.
- Over the past 5 years the stock has fallen 78.2%, which makes the current price a live test of whether the market is now paying an appropriate amount for STAAR Surgical's cash flows.
- An investigation into possible fiduciary breaches by certain officers and directors may affect how investors think about governance, which can influence confidence in how future cash flows are managed and allocated.
- Prefer to judge STAAR Surgical on sales? See why STAAR Surgical's 3.7x P/S tells a different valuation story.
For investors, the debate is whether STAAR Surgical's current share price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) intrinsic value estimate.
If you are weighing whether STAAR Surgical's recent share price moves line up with its cash flow potential, it can help to compare that question with 30 high quality undervalued stocks.
Is STAAR Surgical Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash STAAR Surgical can return to shareholders over time. Latest twelve month free cash flow shows a loss of $19.10 million, so the valuation leans heavily on an eventual recovery to positive cash generation rather than current conditions. The projections assume growing free cash flow over the coming decade, rising into the tens of millions of dollars a year, which supports an intrinsic value that the model places modestly above the current share price of $25.24.
Because that outlook rests on a shift from cash burn to consistent surplus, the story hinges on execution and capital discipline more than on near term earnings. The investigation into possible fiduciary breaches by certain STAAR Surgical officers and directors helps explain why the price may still lag the cash flows implied by this DCF work, since some investors may be applying a governance discount. You can see how the current valuation compares with the full cash flow based estimate in more detail here. Find out what STAAR Surgical could be worth using our Discounted Cash Flow (DCF) estimate.
The STAAR Surgical Narrative: What Would Justify Today's Price?
Narratives for STAAR Surgical pick up where the DCF puzzle leaves off by explaining which paths for growth, profitability and earnings would need to occur for the stock to be worth materially more or materially less than it is today on Simply Wall St's Community page. Each idea connects its number to a clear view on how STAAR Surgical's growth, margins and risk profile might change, giving you something concrete to test against new information.
Community views on STAAR Surgical are split between a potential recovery story built on lens demand and margins, and a more cautious perspective focused on China reliance and governance risk.
Bull case: 10% undervalued
"The global shift toward lens-based refractive procedures, backed by STAAR Surgical’s market report showing declining laser volumes and rising phakic implantable lens adoption in the U.S.…"
Discover why this Narrative puts STAAR Surgical at 10% undervalued.
Bear case: 33% overvalued
"Although China currently provides strong EVO and EVO Plus adoption with over 100% year over year net sales growth and a higher priced premium mix, the company is increasingly dependent on this single market…"
Explore why this Narrative puts STAAR Surgical at 33% overvalued.
One more STAAR Surgical check that belongs beside the price chart
Before you weigh STAAR Surgical purely on cash flows and community narratives, it helps to know that Simply Wall St's broader review has flagged specific concerns that sit outside this valuation work. Take a closer look at 1 warning sign before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com